Expertise in
67
conditions

Dr. Ying Zhuo

Hematology Oncology | Hematology | Oncology
Kadlec Regional Medical Center
7360 W Deschutes Ave, 
Kennewick, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
67
conditions
Kadlec Regional Medical Center
7360 W Deschutes Ave, 
Kennewick, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ying Zhuo is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Zhuo is highly rated in 67 conditions, according to our data. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, and Paget Disease of the Breast. Dr. Zhuo is currently accepting new patients.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Hospital Affiliations
Good Shepherd Medical Center
Prosser Memorial Hospital
Trios Health
Lourdes Medical Center
Kadlec Regional Medical Center
Languages Spoken
English
Afrikaans
Hindi
Mandarin
Russian
Spanish
Ukrainian
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Prominence Health
  • EPO
  • PPO

Locations

KADLEC REGIONAL MEDICAL CENTER
7360 W Deschutes Ave, Kennewick, WA 99336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)
Enrollment Status: Completed
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

97 Total Publications

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Journal: Journal of comparative effectiveness research
Published: December 06, 2024
Similar Doctors
Expertise in
80
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Oncology | Hematology
Expertise in
80
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Oncology | Hematology

Kadlec Regional Medical Center

7360 W Deschutes Ave, 
Kennewick, WA 
 (0.1 mi)
509-783-0144
Languages Spoken:
English, Castilian, Catalan, Filipino, French, Italian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Gamboa is a Hematologist Oncology specialist and an Oncologist in Kennewick, Washington. Dr. Gamboa is highly rated in 80 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Colorectal Cancer. Dr. Gamboa is currently accepting new patients.

Expertise in
88
conditions
Dr. Rangaswamy A. Chintapatla
Oncology | Hematology Oncology | Hematology
Expertise in
88
conditions
Dr. Rangaswamy A. Chintapatla
Oncology | Hematology Oncology | Hematology

Kadlec Regional Medical Center

1050 W Elm Ave, Suite 160, 
Hermiston, OR 
 (25.4 mi)
541-564-1810
Languages Spoken:
English, Hindi, Kannada, Korean, Punjabi, Romanian, Russian, Spanish, Telugu, Ukrainian, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Rangaswamy Chintapatla is an Oncologist and a Hematologist Oncology provider in Hermiston, Oregon. Dr. Chintapatla is highly rated in 88 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Myelodysplastic Syndrome (MDS), and Familial Colorectal Cancer. Dr. Chintapatla is currently accepting new patients.

Expertise in
40
conditions
Dr. Nattamol Hosiriluck
Hematology Oncology | Hematology | Oncology
Expertise in
40
conditions
Dr. Nattamol Hosiriluck
Hematology Oncology | Hematology | Oncology

Kadlec Regional Medical Center

7360 W Deschutes Ave, 
Kennewick, WA 
 (0.1 mi)
509-783-0144
Languages Spoken:
English, Japanese, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nattamol Hosiriluck is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Hosiriluck is highly rated in 40 conditions, according to our data. Her top areas of expertise are Neuroendocrine Tumor, Upper Tract Urothelial Carcinoma (UTUC), Colorectal Cancer, and Familial Colorectal Cancer. Dr. Hosiriluck is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zhuo's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 49 Advanced Conditions
    View All 139 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile